Quest Diagnostics is the volume-driven leader of the US clinical-lab market, compounding revenue ~11% on rising testing volumes and a relentless acquisition cadence. Four straight earnings beats, a freshly raised FY26 EPS guide ($10.63–$10.83), low-0.6 beta and an undemanding ~18.5x forward PE make this the rare defensive name that is also breaking out. Price sits just below its 52-week high, riding clean above all three EMAs StockAnalysis· live.
Quest Diagnostics is one of the two national leaders of US clinical laboratory testing, processing billions of tests a year across routine bloodwork, advanced diagnostics, cancer genomics, and wellness panels. The model is fundamentally volume-driven: more requisitions flow through a fixed lab network, and incremental volume drops to the bottom line at high marginal economics. Revenue compounds through a dual engine — organic testing-volume growth plus a steady cadence of bolt-on hospital-lab and regional-lab acquisitions Quest IR· 2026.
The growth frontier is advanced diagnostics: in 2026 Quest deepened its oncology footprint with a multi-year clinical alliance built around its Haystack MRD circulating-tumor-DNA (ctDNA) test for minimal-residual-disease monitoring — positioning the company in the fast-growing liquid-biopsy market rather than just commodity bloodwork Yahoo Finance· 2026. The moat is scale (lowest cost per test), a national patient-service-center and phlebotomy footprint, and entrenched payer/health-system contracts — a structurally defensive business that grows steadily through cycles.
| Metric | Value | Signal |
|---|---|---|
| Revenue (TTM) | $11.28B | +11.0% YoY |
| EBITDA (TTM) | $2.33B | 20.7% margin |
| Net Income (TTM) | $1.08B | Profitable |
| Gross Margin | 33.2% | Stable |
| Operating Margin | 14.3% | Healthy |
| Net Margin | 9.5% | Solid |
| ROE | 14.3% | Quality |
| EPS (TTM) | $9.05 | Growing |
| Cash | $0.39B | |
| Total Debt | $6.41B | Net Debt/EBITDA 2.6x |
| Fwd P/E | 18.5x | Reasonable |
| Analyst Target | $223.44 | +10% upside · Buy |
This is a high-quality defensive compounder, not a hyper-grower. Double-digit revenue growth (~11%) with a 14.3% ROE and ~21% EBITDA margins is exactly the profile that earns a market-multiple. At ~18.5x forward EPS against the raised $10.63–$10.83 guide, the valuation is undemanding — nowhere near nosebleed territory — and analysts still see ~10% upside to a $223 average target. The one honest caveat is leverage: net debt of ~$6.0B (2.6x EBITDA) is manageable for a stable cash generator but is a real line item, which is precisely why the April 2026 note offering was a refinancing, not new dilution.
No active equity ATM, no toxic convertibles, no stock-funded M&A, no aggressive boutique underwriters. The share count is shrinking, not growing.
The only recent SEC capital-markets event is the April 2026 424B2: a $500M offering of 5.000% senior NOTES due 2036 — pure debt, used to repay the $500M 3.45% notes maturing June 2026. This is balance-sheet refinancing, not equity issuance, and the underwriters were Goldman Sachs, J.P. Morgan and Mizuho — bulge-bracket banks, not the toxic-financing boutiques (Wainwright, Maxim, Dawson James) that signal death-spiral dilution PR Newswire· apr 2026. Diluted shares have fallen from ~127M to ~112.5M over recent years on consistent buybacks StockAnalysis Balance Sheet· jun 2026. SEC EDGAR (CIK 0001022079) shows no active equity shelf draw, no PIPE, no warrant overhang SEC EDGAR· jun 2026.
| RSI (14) | 62.1 |
| Price | $203.06 |
| EMA 20 | $197.39 |
| EMA 50 | $195.60 |
| EMA 200 | $190.38 |
| ATR (14) | $4.58 |
| Ext. vs EMA20 | +2.9% |
Textbook bullish structure. Price ($203.06) > EMA20 ($197.39) > EMA50 ($195.60) > EMA200 ($190.38) — a clean, ordered stack with no overhead resistance until the 52-week high at $213.50. RSI 62.1 sits in the healthy-momentum zone, not yet overbought. At only +2.9% above the EMA20 the stock is not over-extended, so a buy-limit just under spot offers a low-risk entry into an established uptrend. The tight ATR of $4.58 (~2.3%) keeps risk well-defined for a stop below the EMA50 cluster Finviz· live.
A defensive, recession-resistant cash generator with a low 0.59 beta. The principal risks are structural-industry (reimbursement) and balance-sheet (leverage), not existential.
DGX is a recession-resistant essential-services business: people get blood tested in good times and bad, which is why beta sits at 0.59. There is no dilution risk, no cash-burn risk, no going-concern question. The two genuine watch-items — Medicare/PAMA reimbursement pressure and the M&A-driven growth algorithm — are industry-structural and well-understood, not company-specific red flags. Leverage at 2.6x EBITDA is normal for a stable cash compounder. This is about as low-drama as an A+ momentum setup gets.
Buy a high-quality defensive compounder while it is breaking out, not when it is over-extended. DGX trades at ~18.5x forward earnings against a freshly raised FY26 guide ($10.63–$10.83), has beaten estimates four quarters running, and sits in a clean EMA stack just below its 52-week high. A buy-limit at $201.69 (just under spot) with a stop below the EMA50 cluster gives a 2.0R move to a 52-week-high breakout (TP1) and 3.2R to a new-high extension above the $223 analyst target (TP2). R/R = (217.27 − 201.69) / (201.69 − 193.90) = 2.0 at TP1.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from DailyTickers Gateway, Yahoo Finance, StockAnalysis.com, MarketBeat, and SEC EDGAR. Accuracy is not guaranteed.